Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | — |
The patient took two capsules of Vivotif at the same time on the first day; The patient took two capsules of Vivotif at the same time on the first day; Case reference number US-BN-2024-002262 is a spontaneous case initially received from nurse via agency (reference number: USBAV24-1800) on 29-Jul-2024 and concerns a patient of unknown age or gender. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the two capsules of Vivotif on the first day at the same time (batch number: unknown), via unknown route and for unknown indication (explicitly coded as 'vaccine overdose' and 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240729-5a47f3 to US-BAVARIAN NORDIC A/S-US-BN-2024-002262, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A patient of unknown demographics took two capsules of Vivotif on the same day, which is considered overdose and inappropriate schedule of product administration. No associated adverse events were reported. Overdose and inappropriate schedule of product administration are listed per company convention. The patient's medical history and concomitant medication details were not provided. The events are not related to Vivotif, but to human error. The case is non-serious.; Sender's Comments: A patient of unknown demographics took two capsules of Vivotif on the same day, which is considered overdose and inappropriate schedule of product administration. No associated adverse events were reported. Overdose and inappropriate schedule of product administration are listed per company convention. The patient's medical history and concomitant medication details were not provided. The events are not related to Vivotif, but to human error. The case is non-serious.
Comments: None.